Stephanie Sill, NP
Acute Care · North Chesterfield, VANPI 1003496563
Payments from drug & device makers
Across 668 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Medtronic$1K
- UCB, Inc.$1K
- Biogen$1K
- Teva Pharmaceuticals USA, Inc.$771
- AstraZeneca$732
- plus $8K from 49 others
What the payments were for
- Travel & lodging$6084%
- Food & beverage$13,79594%
- Education$2472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCEPT PC BRAINSENSE$783
- Leqembi$352
- OCREVUS$245
- AUSTEDO$127
- UPLIZNA$125
- VYALEV$125
- Nayzilam$124
- Austedo XR$121
How this compares
$14,649 in reported general payments places this provider in the 95th percentile of 599 acute care providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 38 | $186,542 |
| AustedoDeutetrabenazine | 14 | $138,680 |
| Avonex (4 Pack)Interferon Beta-1a | 16 | $126,157 |
| MayzentSiponimod | 13 | $124,910 |
| RytaryCarbidopa/Levodopa | 76 | $86,562 |
| AptiomEslicarbazepine Acetate | 18 | $63,452 |
| EpidiolexCannabidiol (Cbd) | 17 | $60,977 |
| QuliptaAtogepant | 41 | $47,588 |
| XcopriCenobamate | 20 | $43,501 |
| Nurtec OdtRimegepant Sulfate | 22 | $33,954 |
| Aimovig AutoinjectorErenumab-Aooe | 24 | $21,473 |
| Glatiramer Acetate | 13 | $17,982 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 630 | $17,949 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $16,364 |
| BriviactBrivaracetam | 11 | $15,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $83 | $186,54238 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $771 | $138,68014 claims |
| BiogenAvonex (4 Pack) | $1,023 | $126,15716 claims |
| NovartisMayzent | $332 | $124,91013 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide | $363 | $93,122110 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $17 | $63,45218 claims |
| AbbVieQulipta | $1,479 | $47,58841 claims |
| SK Life Science, Inc.Xcopri | $539 | $43,50120 claims |
| PfizerNurtec Odt, Dilantin | $233 | $41,15551 claims |
| UCB, Inc.Briviact, Neupro | $1,042 | $25,28023 claims |
| Upsher-smith Laboratories LLCTopiramate | $41 | $1,260101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 599 acute care providers in Virginia.
Other acute care in North Chesterfield
- Sarah W ShermanNorth Chesterfield$41K
- Amy ShaverNorth Chesterfield$8K
- Shaina SaufleyNorth Chesterfield$7K
- Candice OcampoNorth Chesterfield$7K
- Ashley van LithNorth Chesterfield$4K
- Rachel DukeRichmond$751K
- Julia KingNorfolk$99K
- Sarah KennedyNorfolk$57K
- Tamara StephensDeltaville$30K
- Debra CastnerNassawadox$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.